Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company focused on innovative and generic medicines. The company develops and markets therapies across oncology, anesthesia, contrast agents, autoimmune diseases, metabolic disorders and other specialty areas. Hengrui has invested heavily in research and development to expand from traditional generics into novel drugs and biologics. Its performance depends on Chinese healthcare policy, hospital procurement, reimbursement decisions, clinical trial progress, regulatory approvals and competition in both innovative and generic drug markets.